Swiss Foundation for People with Rare Diseases Combines GENALICE and Knome Solutions to Improve DNA Analysis

HARDERWIJK, the Netherlands and CAMBRIDGE, Mass – October 1, 2014 – Today GENALICE and Knome, Inc. USA jointly announced that the Swiss Foundation for People with Rare Diseases has chosen to use their solutions in tandem to improve the Foundation’s processing and analysis of their Next-Generation Sequencing (NGS) data. GENALICE MAP is an ultra-fast and highly accurate NGS data preprocessing solution and will be connected to Knome’s informatics and genomics interpretation system, the knoSYS® platform.

“In the era of high volume NGS data production, a streamlined and affordable pipeline for data processing and analysis is key,” explains Gabor Matyas from the Foundation. “The combination of the solutions of GENALICE and Knome allows our work to advance considerably. With GENALICE MAP, we significantly reduce the NGS data bottlenecks for align and call with regard to speed, quality, and cost. The connection to the knoSYS then takes our analysis to the next step by enabling the annotation and interpretation of our human NGS data. This unique solution gives us unprecedented control over our data from end-to-end.”

The opportunity for the two companies to work together was initiated by their joint customer, but comments Hans Karten, CEO of GENALICE, “We picked up the phone to discuss the possibility of collaborating and from the first moment, the synergy between the companies was excellent. Not only our teams, but also the products are a perfect match.”

Added CEO and President of Knome, Wolfgang Daum, “The Swiss Foundation for People with Rare Diseases represents an incredible opportunity for GENALICE and Knome to work together on creating a system unlike any other. We are eagerly awaiting the results they are able to achieve using the combined strengths of both platforms.”

About Knome, Inc.
Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to smooth the healthcare industry’s transition to molecular-based, precision medicine.

About GENALICE
GENALICE is a highly innovative biomedical big data company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, it introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE can be found at www.genalice.com.